[go: up one dir, main page]

WO2008006007A3 - Régulateur de la conductance transmembranaire de la mucoviscidose (cftr) défectueux provoquant une synthèse accrue de sphingolipide - Google Patents

Régulateur de la conductance transmembranaire de la mucoviscidose (cftr) défectueux provoquant une synthèse accrue de sphingolipide Download PDF

Info

Publication number
WO2008006007A3
WO2008006007A3 PCT/US2007/072801 US2007072801W WO2008006007A3 WO 2008006007 A3 WO2008006007 A3 WO 2008006007A3 US 2007072801 W US2007072801 W US 2007072801W WO 2008006007 A3 WO2008006007 A3 WO 2008006007A3
Authority
WO
WIPO (PCT)
Prior art keywords
cystic fibrosis
cftr
causes increased
sphingolipid synthesis
transduction regulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/072801
Other languages
English (en)
Other versions
WO2008006007A2 (fr
Inventor
Tilla Worgall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of WO2008006007A2 publication Critical patent/WO2008006007A2/fr
Publication of WO2008006007A3 publication Critical patent/WO2008006007A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des procédés et des compositions pour le traitement de la mucoviscidose et des infections P. aeruginosa par administration d'une quantité thérapeutique d'un ou de plusieurs agents inhibant la nouvelle synthèse de sphingolipide ou les voies de recyclage.
PCT/US2007/072801 2006-07-03 2007-07-03 Régulateur de la conductance transmembranaire de la mucoviscidose (cftr) défectueux provoquant une synthèse accrue de sphingolipide Ceased WO2008006007A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81835106P 2006-07-03 2006-07-03
US60/818,351 2006-07-03

Publications (2)

Publication Number Publication Date
WO2008006007A2 WO2008006007A2 (fr) 2008-01-10
WO2008006007A3 true WO2008006007A3 (fr) 2008-10-30

Family

ID=38895458

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/072801 Ceased WO2008006007A2 (fr) 2006-07-03 2007-07-03 Régulateur de la conductance transmembranaire de la mucoviscidose (cftr) défectueux provoquant une synthèse accrue de sphingolipide

Country Status (1)

Country Link
WO (1) WO2008006007A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
US20100080807A1 (en) * 2008-09-26 2010-04-01 National Taiwan University Methods and Compositions for Treating Viral Hemorrhagic Fever
ITFE20080032A1 (it) * 2008-10-23 2010-04-24 Azienda Ospedaliera Istituti Ospit Alieri Di Vero Effetto anti infiammatorio del miglustat cellule dell'epitelio bronchiale
US20150258043A1 (en) * 2012-10-15 2015-09-17 Yeda Research And Development Co. Ltd. Use of sphingoid long chain bases and their analogs in treating and preventing bacterial infections
US10406127B2 (en) 2014-07-25 2019-09-10 Laurent Pharmaceuticals Solid oral formulation of fenretinide
ES3009527T3 (en) * 2014-07-25 2025-03-27 Laurent Pharmaceuticals Solid oral formulation of fenretinide
WO2020011745A2 (fr) * 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Oligonucléotides antisens ciblant cers6
WO2020011744A2 (fr) * 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Oligonucléotides antisens ciblant cers5
IL260690A (en) 2018-07-19 2018-12-31 Yeda Res & Dev Sphingosine derivatives and their use against pulmonary bacterial infections
US12391947B2 (en) 2018-11-29 2025-08-19 University Of Massachusetts Modulation of SPTLC1 via recombinant adeno-associated vectors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070197656A1 (en) * 2004-03-02 2007-08-23 Stan Kubow Compositions and methods for preventing or treating an inflammatory response

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070197656A1 (en) * 2004-03-02 2007-08-23 Stan Kubow Compositions and methods for preventing or treating an inflammatory response

Also Published As

Publication number Publication date
WO2008006007A2 (fr) 2008-01-10

Similar Documents

Publication Publication Date Title
WO2008006007A3 (fr) Régulateur de la conductance transmembranaire de la mucoviscidose (cftr) défectueux provoquant une synthèse accrue de sphingolipide
WO2007002559A8 (fr) Modulateurs des lxr a base de pyrazoles
WO2007104053A3 (fr) Inhibiteurs de la 8-hétéroarylpurine mnk2 pour le traitement de troubles métaboliques
WO2007111994A3 (fr) Composés et méthodes pour traitement de troubles associés à un stress du réticulum endoplasmique
IL189178A0 (en) Thiazolyl derivatives and pharmaceutical compositions containing the same
WO2007138282A3 (fr) Nouveaux composés
WO2005046575A3 (fr) Prodrogues a base d'acides amines
WO2007075895A3 (fr) Derives heterocycliques utilises comme modulateurs de canaux ioniques
UA92641C2 (ru) Комбинированная препаративная форма, которая содержит амлодипин и лозартан
WO2008070129A3 (fr) Compositions et procédés pour le traitement de maladie inflammatoire
IL189298A0 (en) 3.5-disubstituted phenyl-piperidines as modulators of dopamine meurotransmission
WO2008070268A3 (fr) Compositions pharmaceutiques
GB2466912A (en) Compositions and methods for treating lysosomal disorders
ZA200806778B (en) N-Hydroxyacrylamide compounds
WO2007053844A3 (fr) Préparations et méthodes pour le traitement de troubles inflammatoires
WO2007117544A3 (fr) Conjugés carnitine d'adamantanamines et dérivés de néramexane comme promédicaments doubles pour utilisations variées
WO2007044325A3 (fr) Inhibiteurs de l'interaction du domaine apoe4 et methodes d'utilisation
MX2009005351A (es) Compuestos utiles para tratar trastornos neurodegenerativos.
WO2008084171A3 (fr) Utilisation du nepafenac ou ses derives pour le traitement de la rosacee, l' acne, le psoriasis et la dermatite atopique
WO2009073138A3 (fr) Traitement du syndrome métabolique par de nouveaux amides
WO2007143587A8 (fr) Procédés d'administration de médicament
WO2006132928A3 (fr) Methodes et compositions permettant de traiter une inflammation
WO2010023196A3 (fr) Nouveaux dérivés de pipéridine-propionamide et leur utilisation en tant qu'inhibiteurs du recaptage des neurotransmetteurs monoamines
WO2008014232A3 (fr) Formulations pharmaceutiques utilisées dans le traitement de la maladie d'alzheimer
WO2008006099A3 (fr) Traitement de troubles psychiatriques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07840348

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07840348

Country of ref document: EP

Kind code of ref document: A2